US OptionsDetailed Quotes

SAGE250117C27500

Watchlist
  • 0.01
  • 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

News

Comments

    Jaguar8
    Jaguar8
    18 hours ago
    ADDED NEWS
    $Sage Therapeutics (SAGE.US)$
    Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
    Friday, 10th January at 6:49 pm
    No Shareholder Action Required at This Time
    Sage Therapeutics, Inc. (NASDAQ: SAGE) ("The Company"), today confirmed that Biogen Inc. (NASDAQ: BIIB) ("Biogen") has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share...
    3
    Jaguar8
    Jaguar8
    19 hours ago
    NEWS
    $Sage Therapeutics (SAGE.US)$
    Biogen Inc - Submits Non-Binding Proposal to Buy All Outstanding Shares of Sage Therapeutics' Common Stock Not Owned by Biogen for $7.22/Share in Cash
    Jaguar8
    Jaguar8
    Oct 17, 2024 06:42
    NEWS
    $Sage Therapeutics (SAGE.US)$
    Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
    Sage Therapeutics has announced a strategic reorganization to support the launch of ZURZUVAE for postpartum depression and focus on pipeline development. The plan includes a workforce reduction of approximately 33%, affecting over 165 employees. This restructuring aims to extend the company's cash runway and position it for long-term ...
    Jaguar8
    Jaguar8
    Oct 8, 2024 05:31
    NEWS
    $Sage Therapeutics (SAGE.US)$
    Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
    Sage Therapeutics (Nasdaq: SAGE) announced topline results from the Phase 2 LIGHTWAVE Study of dalzanemdor (SAGE-718) in treating mild cognitive impairment and mild dementia in Alzheimer's Disease. The study did not demonstrate a statistically significant difference from basel...
    Sikander KHAN
    Sikander KHAN
    Jul 29, 2024 08:26
    Don't expect exceptional Q2 results.
    $Sage Therapeutics (SAGE.US)$ Stock is good, but sentiment is negative. I don't see any significant and sustainable upside by Q3. Another 20% to 30% downside is 'Likely'
    My research and analysis are not advice or recommendations. It's for information and knowledge purposes only. Any research , analysis, information, or other material received should not be construed as individualized investment advice. Investment decisions should be made as part of financial ...
Read more